TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast Cancer
Rachel O. Abelman(Massachusetts General Hospital), Aditya Bardia(Harvard University), Elena Bitman(Massachusetts General Hospital), Beverly Moy(Massachusetts General Hospital), Laura M. Spring(Massachusetts General Hospital), Bogang Wu(George Washington University), Geoffrey Fell(Dana-Farber Cancer Institute), Seth A. Wander(Massachusetts General Hospital), Bryanna L. Norden(Massachusetts General Hospital), Ryan B. Corcoran(Harvard University), Andreas Varkaris(Beth Israel Deaconess Medical Center), Neelima Vidula(Harvard University), Win Thant(Massachusetts General Hospital), Haley Barnes(Massachusetts General Hospital), Leif W. Ellisen(Harvard University), Caroline Weipert(Guardant (United States)), Dejan Juric(Massachusetts General Hospital), Annika Putur(Massachusetts General Hospital), Steven J. Isakoff(Harvard University), Ting Liu(Massachusetts General Hospital), Arielle J. Medford(Harvard University)
Cited by 39
Related Papers
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
|Nature Communications|2017|999
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2010|983